HUTCHMED (China) Limited has started a registrational Phase III trial of its investigational BTK inhibitor HMPL-760 in combination with R-GemOx for patients in China with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) who are ineligible for transplantation. The first patient was dosed on March 20, 2026.
The randomized, double-blind study will enroll approximately 240 patients and compare HMPL-760 plus R-GemOx with placebo plus R-GemOx. Primary goals are progression-free survival and overall survival, with additional measures including response rates, duration of response, safety and pharmacokinetics.
HMPL-760 is a third generation, non-covalent BTK inhibitor targeting both wild-type and C481S‑mutated BTK. Earlier Phase II data in the same setting showed encouraging improvements in response and survival measures with a manageable safety profile, supporting advancement to this Phase III trial. HUTCHMED retains all global rights to HMPL-760.
HUTCHMED (China) Ltd Deputy Chief Financial Officer Lorenso Chiu has filed an initial Form 3 detailing his equity interests in the company. He reports multiple share options over American depositary shares with exercise prices between $10.7500 and $27.9400, vesting over four years and expiring between 2030 and 2033. He also holds Long Term Incentive Plan awards over 8,108 ordinary shares indirectly through a plan trustee, plus 46,007 ordinary shares and 8,475 American depositary shares directly. Each American depositary share represents five ordinary shares.
HUTCHMED (China) Ltd director and CEO/CSO Su Wei-guo filed an initial ownership report showing a sizeable equity stake. He holds share options over 1,000,000 ordinary shares expiring in 2027 and another 1,000,000 ordinary shares expiring in 2028, plus additional options over American depositary shares with exercise prices between $22.09 and $35.21 per ADS and expirations from 2030 to 2031. Further options cover 1,405,767 ordinary shares expiring in 2034 and 1,493,435 ordinary shares expiring in 2035. He also directly owns 3,563,905 ordinary shares and 237,063 American depositary shares, and has indirect Long Term Incentive Plan awards over 39,862 and 169,977 ordinary shares held by a plan trustee. Each American depositary share represents 5 ordinary shares.
HUTCHMED (China) Limited reports the vesting of non-performance based awards under its Long Term Incentive Plan. On March 13, 2026, awards granted on March 13, 2024 to Dr. Weiguo Su, Executive Director, Chief Executive Officer and Chief Scientific Officer, vested into 19,913 ordinary shares.
The vesting occurred at a price of nil and outside a trading venue, reflecting equity-based compensation rather than a market transaction. The notification is made in line with UK Market Abuse Regulation requirements and relates to ordinary shares of US$0.10 par value.
HUTCHMED (China) Ltd Chief Financial Officer Cheng Chig Fung filed an initial ownership report showing existing equity holdings, not new trades. He holds several share options over American depositary shares with exercise prices of $22.0900, $27.9400, $10.7500 and $12.5100, expiring between 2030 and 2033.
The filing also lists 1,463,698 ordinary shares and 56,693 American depositary shares held directly, plus 38,567 ordinary shares held indirectly through a Long Term Incentive Plan. Each American depositary share represents 5 ordinary shares, and plan awards are scheduled to vest in 2027 subject to vesting criteria.
HUTCHMED (China) Limited reported that long-term incentive awards granted on June 5, 2023 under its Long Term Incentive Plan have vested following the announcement of its 2025 annual results. On March 10, 2026, 524,079 ordinary shares vested to Dr Weiguo Su and 202,238 ordinary shares vested to Mr Johnny Cheng, totaling 726,317 shares.
These awards vested at nil price and relate to ordinary shares of US$0.10 each. Both executives are classified as persons discharging managerial responsibilities, and the transactions took place outside a trading venue, in line with UK Market Abuse Regulation notification requirements.
HUTCHMED (China) Ltd director Yang Ling filed an initial Form 3, formally reporting their beneficial ownership position as an insider of the company. The available data show no reported purchases, sales, acquisitions, or disposals of HUTCHMED securities in this filing.
HUTCHMED (China) Ltd director Daniel Shao Weng Tan filed an initial insider ownership report on Form 3. The filing lists him as a director of the company and does not report any insider buy, sell, acquisition, or disposition transactions at this time.
HUTCHMED (China) Ltd director Renu Bhatia has filed an initial Form 3 reporting her holdings in the company. The filing shows direct beneficial ownership of 16,000 ordinary shares following the reported position, with no specific buy or sell transaction indicated in this disclosure.
HUTCHMED (China) Ltd director Tony Shu Kam Mok filed an initial ownership report on Form 3. He reported beneficial ownership of 27,341 American depositary shares. Each American depositary share represents 5 ordinary shares of HUTCHMED.